J Pediatric Infect Dis Soc . Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study

[tetano]

J Pediatric Infect Dis Soc


. 2023 Mar 17;piac124.
doi: 10.1093/jpids/piac124. Online ahead of print.
Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study


Gilad Sherman ^{1 2} , Gabriella S Lamb ^{1 2} , Tanvi S Sharma ^{1 2} , Elizabeth C Lloyd ³ , Jerod Nagel ⁴ , Nada N Dandam ⁴ , Carlos R Oliveira ⁵ , Hassan S Sheikha ⁵ , Brenda I Anosike ⁶ , Philip Lee ⁶ , Surabhi B Vora ⁷ , Karisma Patel ⁸ , Paul K Sue ⁸ , Beenish Rubbab ⁸ , April M Yarbrough ⁹ , Lakshmi Ganapathi ^{1 2} , Mari M Nakamura ^{1 2 10}



Affiliations

• PMID: 36928172
• DOI: 10.1093/jpids/piac124

Abstract

Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.

Keywords: COVID-19; SARS-CoV-2; bamlanivimab and etesevimab; casirivimab and imdevimab; monoclonal antibodies; pediatric.